版权说明 操作指南
首页 > 成果 > 详情

Carbapenem-resistant Gram-negative bacteria exhibiting clinically undetected cefiderocol heteroresistance leads to treatment failure in a murine model of infection

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Liu, Hongwei;Zhou, Peng;Ma, Peng;Liu, Yaqin;Zhang, Yingfeng;...
作者机构:
[Liu, Hongwei; Zhou, Peng; Ma, Peng; Liu, Yaqin; Xu, Lingqing; Yin, Weiguo; Li, Linhai; Lu, Yang] The Affiliated Qingyuan Hospital (Qingyuan People's Hospital),Guangzhou Medical University, Qingyuan, China
[Zhang, Yingfeng] Department of Public Health Laboratory Sciences, School of Public Health, Hengyang Medical College, University of South China, Hengyang, Hunan Province, China
[Li, Qiwei] Department of Laboratory Medicine, The Second Affiliated Hospital, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
[Yuan, Wenchang] KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guangdong Province, China
语种:
英文
关键词:
Heteroresistance;cefiderocol;gene mutation;Failure treatment;Carbapenem resistance
期刊:
Frontiers in Microbiology
ISSN:
1664-302X
年:
2025
卷:
16
页码:
1496514
机构署名:
本校为其他机构
院系归属:
公共卫生学院
摘要:
ABSTRACTCarbapenem-resistant (CR) Gram-negative pathogens, prioritized by the WHO as critical threats, face limited therapeutic options, with cefiderocol (CFD) emerging as a promising siderophore cephalosporin. This study investigated the prevalence, clinical impact, and genetic mechanisms of cefiderocol heteroresistance (CFD-HR) in 407 CR and ESBL-producing clinical isolates from China, where CFD remains unapproved. Population analysis profiles (PAPs) revealed CFD-HR rates of 17.4% (16/92) in carbapenem-resistant A. baumannii (CRAB), 27.9% (24...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com